NFlection Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
714 Woodcrest Rd, Wayne, Pennsylvania, 1...Phone Number
(617) 875-4559Website
www.nflectionrx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About NFlection Therapeutics
NFlection Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted topical therapies for rare dermatological diseases. The company focuses on addressing the needs of patients with conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks. NFlection is developing first-in-class MEK inhibitors aimed at treating these RAS-mediated disorders driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. Their innovative approach seeks to change the landscape of treatment for these rare conditions.Explore more
Popular SearchesNflection Therapeutics IncNFlection TherapeuticsNFlection Therapeutics AsSIC Code 28,283NAICS Code 32,325Show moreNFlection Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NFlection Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if NFlection Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when NFlection Therapeutics launches new products
Click to see if NFlection Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on NFlection Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at NFlection Therapeutics
Check out if NFlection Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once NFlection Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
NFlection Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to NFlection Therapeutics
Compare insights from companies similar to NFlection Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NFlection Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NFlection Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NFlection Therapeutics.
NFlection Therapeutics financials insights
Gather financial insights about NFlection Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$20M
NFlection Therapeutics Tech Stack
A closer look at the technologies used by NFlection Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Funding
NFlection Therapeutics News & Media
Children’s Tumor Foundation Expands into a New Strategic Chapter as...
The Children’s Tumor Foundation (CTF) announced a significant impact investment in a Phase 2b clinical trial at NFlection Therapeutics. The trial involves NFX-179, a topical (on the skin) treatment... (PRWeb January 10, 2023) Read the full story at https://www.prweb.com/releases/childrens_tumor_foundation_expands_into_a_new_strategic_chapter_as_impact_investor_in_nf_research/prweb19105835.htmNFlection Therapeutics Appoints William Hodder as CEO and Expands Leadership Team to Accelerate Development of Targeted Treatments for Rare Diseases
WAYNE, Pa.--(BUSINESS WIRE)--NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it has appointed William Hodder as CEO. The company also named Gerd Kochendoerfer, Ph.D., as Chief Operating Officer, Libbie Mansell, Ph.D., MBA, as SVP of Global Regulatory Affairs & Quality Assurance, and Patrice Horwath as VP of Clinical Operations. Mr. Hodder brings over 30 years of broad biopharmaceuNFlection Therapeutics Announces Orphan Drug Designation of NFX-179 for the Treatment of Cutaneous Neurofibromatosis Type 1
WAYNE, Pa.--(BUSINESS WIRE)--NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that the Food and Drug Administration (FDA) has granted the company orphan drug designation for NFX-179 for the treatment of cutaneous neurofibromatosis type 1. NFX-179 is a topical, first-in-class, “soft” MEK inhibitor that is currently being evaluated in Phase 2 clinical trials in patients with cutaneous neurofiNFlection Therapeutics' NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial
WAYNE, Pa., May 26, 2021 /PRNewswire/ -- NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare disorders driven by aberrant activation of the RAS pathway (RASopathies), today announced positive results from a...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NFlection Therapeutics
Sign Up For FreeTo access detailed company insights
NFlection Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of targeted topical therapies for rare dermatological diseases. The company focuses on addressing the needs of patients with conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital b... Read More
